Clinical trials: Bone Marrow
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005641
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
The purpose of this study is to evaluate the efficacy and safety of pevonedistat plus azacitidine versus single-agent azacitidine in participants with HR-MDS or CMML, or low-blast AML.
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
- Trial name
- NCT02610777
- Testing
- Azacitidine, Pevonedistat
- Where
- 59 sites in United States, Belgium and 10 more
- Volunteers
- 120 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Severe/Moderate Coronavirus, Chronic Myelomonocytic Leukemia
Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)
The purpose of this study is to provide new insights into the pathophysiology of emergency hematopoiesis detected in severe COVID-19 patients.
- Conditions
- Severe/Moderate Coronavirus, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Old Age
- Trial name
- CALPRO (NCT04953312)
- Testing
- Blood samples
- Where
- France
- Volunteers
- healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Femoroacetabular Impingement, Cartilage Damage
Cartilage Repair Using a Hyaluronic Acid-Based Scaffold With Bone Marrow Aspirate Compared With Microfracture for Focal Articular Cartilage Damage of the Hip
Femoroacetabular impingement (FAI) is a hip disorder resulting from a mismatch of the hip joint, resulting in hip pain and can potentially cause osteoarthritis.
- Trial name
- CHASE (NCT04875767)
- Testing
- HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)
- Sponsor
- McMaster University
Chronic Myelogenous Leukemia, Malignant Melanoma
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
This open label extension study will give an opportunity to the participants that have responded to the treatment with Pegylated-Interferon Alfa-2a (Pegasys) or Recombinant Interferon Alfa-2a (Roferon-A®) in prior clinical…
- Conditions
- Chronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma
- Trial name
- NCT02829775
- Testing
- Pegylated Interferon Alfa-2a, Recombinant Interferon Alfa 2a
- Where
- 8 sites in Bulgaria, Canada and 5 more
- Volunteers
- 9 people
- Sponsor
- Hoffmann-La Roche
Graft vs Host Disease, Oral Manifestations
Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease
The purpose of this study is to perform a randomized, double-blind, clinical trial comparing the topical treatment with clobetasol or dexamethasone for symptomatic oral lesions of chronic graft-versus-host disease.
- Trial name
- NCT01699412
- Testing
- Clobetasol, Dexamethasone
- Where
- 2 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Myelodysplastic Syndrome, Acute Myelogenous Leukemia
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with azacitidine to patients with high-risk myelodysplastic syndromes or acute myelogenous leukemia.
- Trial name
- NCT00324220
- Testing
- MGCD0103
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Mirati Therapeutics Inc.
Leukemia, Lymphoma
New York Blood Center National Cord Blood Program
Umbilical cord blood is used as a source of hematopoietic stem cells for bone marrow reconstitution in patients who would be potential candidates for a bone marrow transplant from an unrelated marrow donor.
- Conditions
- Leukemia, Lymphoma, Genetic Disease, Severe Aplastic Anemia
- Trial name
- NCT00212407
- Testing
- Umbilical Cord Blood Transplantation
- Where
- United States
- Volunteers
- 4,476 people
- Sponsor
- New York Blood Center
Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
This phase I/II trial studies the best dose of venetoclax when given together with azacitidine and pevonedistat and to see how well it works in treating patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Chronic Myelomonocytic Leukemia
- Trial name
- NCT03862157
- Testing
- Azacitidine, Pevonedistat, Venetoclax
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Sinusoidal Obstruction Syndrome, Complications of Bone Marrow Transplant
Using Ultrasound Elastography to Predict Development of SOS
Sinusoidal obstruction syndrome (SOS) is a potentially fatal hepatic veno-occlusive disease-affecting children following bone marrow transplantation (BMT).
- Trial name
- NCT02483481
- Testing
- shear wave ultrasound elastography
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Children's Mercy Hospital Kansas City
Leukemia, Acute Leukemia
Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors
The Sharing Our Strength study is being conducted to help us understand people's experiences with hematopoietic stem cell transplantation and to test a new program designed to help people recover physically and emotionally after…
- Conditions
- Leukemia, Acute Leukemia, Acute Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT00701844
- Testing
- Writing A (Experimental informative writing), Writing B (Experimental noninformative writing), Writing C (Control informative writing)
- Where
- 3 sites in United States
- Volunteers
- 315 people
- Sponsor
- University of North Carolina, Chapel Hill
Myelofibrosis
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and preliminary…
- Trial name
- NCT05371964
- Testing
- Imetelstat sodium, Ruxolitinib
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Geron Corporation
Lymphoma, Quality of Life
Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Studying the long-term effects of cancer treatment in cancer survivors may help improve the ability to plan effective treatment and follow-up care.
- Trial name
- NCT00098566
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Neutropenia
Maintaining a Higher Level of Haemoglobin: Effect on the White Cells After Bone Marrow Transplantation in Children.
The purpose of this study is to determine if maintaining a high hemoglobin level in children that underwent bone marrow transplant will accelerate the neutrophil recovery.
- Trial name
- NCT00937053
- Testing
- Transfusion level 120 g/dL, Transfusion level 70 g/dL, Platelet transfusion
- Where
- 5 sites in Canada
- Volunteers
- 6 people
- Sponsor
- St. Justine's Hospital
Osteochondral Lesions of Talus
Bone Marrow Aspirate Concentrate (BMAC) Supplementation for Osteochondral Lesions
The purpose of this study is to determine the clinical efficacy of the application of bone marrow aspirate concentrate (BMAC) as a supplement to microfracture in the treatment of osteochondral lesions of the talus (OLTs).
- Trial name
- BMAC (NCT02011295)
- Testing
- ankle arthroscopy with debridement and microfracture of the OLT, Bone Marrow Aspirate injection
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Duke University
Critical Limb Ischemia
Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA)
The investigators designed a randomized clinical trial (stem cell emergency life threatening arteriopathy or SCELTA) to compare the therapeutic efficacy of the auto-transplant of enriched circulating EPCs (ECEPCs) with…
- Trial name
- SCELTA (NCT02454231)
- Testing
- Transplantation of circulating CD14+CD34+cells, Transplantation of BM MNC
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- University of Florence
Leukemia, Myelodysplastic Syndromes
Topotecan in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of topotecan in treating patients who have…
- Trial name
- NCT00003675
- Testing
- topotecan hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma Nonhodgkin
Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)
To ascertain the safety of Revlimid® Capsules 2.5 mg or 5 mg under the actual use conditions in patients who received R2 combination therapy with the drug and rituximab for the first time for relapsed or refractory follicular…
- Trial name
- NCT04618081
- Where
- Japan
- Volunteers
- 151 people
- Sponsor
- Celgene
Anemia, Aplastic, Red-Cell Aplasia, Pure
Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
This study will test whether the immune-suppressing drug rituximab can increase blood counts and reduce the need for transfusions in patients with moderate aplastic anemia, pure red cell aplasia, or Diamond Blackfan anemia.
- Conditions
- Anemia, Aplastic, Red-Cell Aplasia, Pure, Anemia, Diamond-Blackfan
- Trial name
- NCT00229619
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myelofibrosis，MF
Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia
We hypothesize that pacritinib leads to modification of the myelofibrosis (MF) disease phenotype, especially related to BM fibrosis and cytopenias; due potentially to its dual effect as an inhibitor of the JAK and NFκB pathways…
- Trial name
- PACRIMYEL (NCT07394153)
- Testing
- Pacritinib
- Where
- 13 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.